Last Updated: November 13, 2026

ALPHAREDISOL Drug Patent Profile

Name: ALPHAREDISOL Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Alpharedisol patents expire, and when can generic versions of Alpharedisol launch?

Alpharedisol is a drug marketed by Merck and is included in one NDA.

The generic ingredient in ALPHAREDISOL is hydroxocobalamin. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the hydroxocobalamin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alpharedisol

A generic version of ALPHAREDISOL was approved as hydroxocobalamin by ACTAVIS on December 31^st, 1969.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ALPHAREDISOL?
What are the global sales for ALPHAREDISOL?
What is Average Wholesale Price for ALPHAREDISOL?

Summary for ALPHAREDISOL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	36
Patent Applications:	15
DailyMed Link:	ALPHAREDISOL at DailyMed

Drug patent expirations by year for ALPHAREDISOL

US Patents and Regulatory Information for ALPHAREDISOL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	ALPHAREDISOL	hydroxocobalamin	INJECTABLE;INJECTION	080778-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

EU/EMA Drug Approvals for ALPHAREDISOL

Subscribe to access the full database, or Start Trial
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
SERB SA	Cyanokit	hydroxocobalamin	EMEA/H/C/000806Treatment of known or suspected cyanide poisoning.Cyanokit is to be administered together with appropriate decontamination and supportive measures.	Authorised	no	no	no	2007-11-23
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.